礼来公司周二表示其每日服用的减肥药丸在后期试验中帮助肥胖和2型糖尿病患者减轻了体重达到了研究的主要目标为该公司在全球范围

智通财经
Aug 26
礼来公司周二表示其每日服用的减肥药丸在后期试验中帮助肥胖和2型糖尿病患者减轻了体重达到了研究的主要目标为该公司在全球范围内申请该药物的批准铺平了道路。 这种治疗方法正逐渐成为减肥和糖尿病药物GLP-1s这一利润丰厚市场中的一种新无针替代方案。更方便的药丸可以增加治疗的供应量并且与目前主导该领域的昂贵的每周注射剂相比更容易获得。与主要竞争对手诺和诺德的类似口服治疗不同礼来公司的药丸没有饮食限制。 在72周的试验期内最高剂量的口服药物orforglipron帮助患者平均减轻10.5%的体重(约10.4公斤)而服用安慰剂的患者仅减重2.2%。若将所有患者(包括中途退出者)纳入分析该药物的减重效果为9.6%。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10